{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:01:50Z","timestamp":1792760510679,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,24]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Psoriasis is a chronic inflammatory skin disease often associated with obesity and metabolic dysfunction, which may worsen disease severity. Glucagon-like peptide-1 receptor agonists, such as semaglutide, have shown metabolic and anti-inflammatory effects, but their impact on psoriasis in patients with obesity and without diabetes remains unclear.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To evaluate the effects of a 6-month semaglutide treatment on psoriasis severity and clinical, metabolic, inflammatory and psychosocial parameters in patients with psoriasis and obesity.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n In this prospective cohort study, 43 patients received weekly semaglutide along with lifestyle counselling. Psoriasis severity (Psoriasis Area and Severity Index, PASI), quality of life (Dermatology Life Quality Index, DLQI), depressive symptoms (Beck Depression Inventory, BDI), nutritional ultrasound and biochemical markers were assessed at baseline and after 6\u2005months. Correlations between PASI improvement (\u0394PASI) and baseline variables and their changes were analysed, adjusting for age and weight loss.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n After 6\u2005months, participants showed significant reductions in PASI (\u201348%), body mass index (BMI), preperitoneal and superficial fat, along with improvements in DLQI, BDI and metabolic markers. Baseline disease severity, depressive symptoms, insulin resistance and preperitoneal fat were negatively associated with PASI improvement. These associations remained significant after adjustment [e.g. Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), r = \u20130.82; preperitoneal fat, r = \u20130.66]. \u0394PASI was most strongly correlated with reductions in superficial fat (r = 0.89), DLQI (r = 0.55) and BDI (r = 0.51). Changes in BMI and glycaemic markers were not significantly associated after adjustment.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n In patients with psoriasis and obesity, semaglutide improves both skin disease and systemic health. The clinical benefit appears associated with specific fat loss and psychosocial improvement, beyond overall weight reduction.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/ced\/llaf473","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:21:57Z","timestamp":1761222117000},"page":"442-450","source":"Crossref","is-referenced-by-count":10,"title":["Dermatological and metabolic benefits of semaglutide in psoriasis with obesity: a 6-month prospective cohort study"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7819-0471","authenticated-orcid":false,"given":"Joana","family":"Nicolau","sequence":"first","affiliation":[{"name":"Vascular and Metabolic Diseases Research Group, Endocrinology Department, Son Ll\u00e0tzer University Hospital, Health Research Institute of the Balearic Islands (IdISBa) , Palma de Mallorca ,","place":["Spain"]},{"name":"Interdisciplinary Group in Neurodegeneration, Vascular and Metabolic Diseases, University of Balearic Islands (UIB), Health Research Institute of the Balearic Islands (IdISBa) , Palma de Mallorca ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Nadal","sequence":"additional","affiliation":[{"name":"Dermatology Department. Son Ll\u00e0tzer University Hospital , Palma de Mallorca ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Sanch\u00eds","sequence":"additional","affiliation":[{"name":"Interdisciplinary Group in Neurodegeneration, Vascular and Metabolic Diseases, University of Balearic Islands (UIB), Health Research Institute of the Balearic Islands (IdISBa) , Palma de Mallorca ,","place":["Spain"]},{"name":"CIBER Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n (CIBERObn), Instituto de Salud Carlos III , 28029 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antelm","family":"Pujol","sequence":"additional","affiliation":[{"name":"Vascular and Metabolic Diseases Research Group, Endocrinology Department, Son Ll\u00e0tzer University Hospital, Health Research Institute of the Balearic Islands (IdISBa) , Palma de Mallorca ,","place":["Spain"]},{"name":"Interdisciplinary Group in Neurodegeneration, Vascular and Metabolic Diseases, University of Balearic Islands (UIB), Health Research Institute of the Balearic Islands (IdISBa) , Palma de Mallorca ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Isabel","family":"Tamayo","sequence":"additional","affiliation":[{"name":"Vascular and Metabolic Diseases Research Group, Endocrinology Department, Son Ll\u00e0tzer University Hospital, Health Research Institute of the Balearic Islands (IdISBa) , Palma de Mallorca ,","place":["Spain"]},{"name":"Interdisciplinary Group in Neurodegeneration, Vascular and Metabolic Diseases, University of Balearic Islands (UIB), Health Research Institute of the Balearic Islands (IdISBa) , Palma de Mallorca ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Sfondrini","sequence":"additional","affiliation":[{"name":"Vascular and Metabolic Diseases Research Group, Endocrinology Department, Son Ll\u00e0tzer University Hospital, Health Research Institute of the Balearic Islands (IdISBa) , Palma de Mallorca ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Grimalt","sequence":"additional","affiliation":[{"name":"Vascular and Metabolic Diseases Research Group, Endocrinology Department, Son Ll\u00e0tzer University Hospital, Health Research Institute of the Balearic Islands (IdISBa) , Palma de Mallorca ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Vascular and Metabolic Diseases Research Group, Endocrinology Department, Son Ll\u00e0tzer University Hospital, Health Research Institute of the Balearic Islands (IdISBa) , Palma de Mallorca ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Nadal","sequence":"additional","affiliation":[{"name":"Dermatology Department. Son Ll\u00e0tzer University Hospital , Palma de Mallorca ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llu\u00eds","family":"Masmiquel","sequence":"additional","affiliation":[{"name":"Vascular and Metabolic Diseases Research Group, Endocrinology Department, Son Ll\u00e0tzer University Hospital, Health Research Institute of the Balearic Islands (IdISBa) , Palma de Mallorca ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"key":"2026022406165968000_llaf473-B1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"2026022406165968000_llaf473-B2","first-page":"663","article-title":"Relationship between psoriasis and metabolic syndrome: a systematic review","volume":"151","author":"Singh","year":"2016","journal-title":"G Ital Dermatol Venereol"},{"key":"2026022406165968000_llaf473-B3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clindermatol.2017.09.005","article-title":"Psoriasis and the metabolic syndrome","volume":"36","author":"Gisondi","year":"2018","journal-title":"Clin Dermatol"},{"key":"2026022406165968000_llaf473-B4","doi-asserted-by":"crossref","first-page":"e1002739","DOI":"10.1371\/journal.pmed.1002739","article-title":"Evidence of a causal relationship between body mass index and psoriasis: a Mendelian randomization study","volume":"16","author":"Budu-Aggrey","year":"2019","journal-title":"PLOS MED"},{"key":"2026022406165968000_llaf473-B5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s13679-020-00380-3","article-title":"Deciphering the association between psoriasis and obesity: current evidence and treatment considerations","volume":"9","author":"Paroutoglou","year":"2020","journal-title":"Curr Obes Rep"},{"key":"2026022406165968000_llaf473-B6","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10654-018-0366-z","article-title":"Body mass index, abdominal fatness, weight gain and the risk of psoriasis: a systematic review and dose\u2013response meta-analysis of prospective studies","volume":"33","author":"Aune","year":"2018","journal-title":"Eur J Epidemiol"},{"key":"2026022406165968000_llaf473-B7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ad.2012.08.003","article-title":"Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications","volume":"105","author":"Carrascosa","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"2026022406165968000_llaf473-B8","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1001\/jamadermatol.2013.722","article-title":"Effect of weight loss on the severity of psoriasis: a randomized clinical study","volume":"149","author":"Jensen","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2026022406165968000_llaf473-B9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jbspin.2018.03.007","article-title":"Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: a systematic review and meta-analysis","volume":"86","author":"Shan","year":"2019","journal-title":"Joint Bone Spine"},{"key":"2026022406165968000_llaf473-B10","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ijo.2015.64","article-title":"Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis","volume":"39","author":"Upala","year":"2015","journal-title":"Int J Obes (Lond)"},{"key":"2026022406165968000_llaf473-B11","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2026022406165968000_llaf473-B12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.medcli.2023.05.021","article-title":"Effects of liraglutide among patients living with psoriasis and obesity","volume":"161","author":"Nicolau","year":"2023","journal-title":"Med Clin (Barc)"},{"key":"2026022406165968000_llaf473-B13","doi-asserted-by":"crossref","first-page":"106941","DOI":"10.1016\/j.medcli.2025.106941","article-title":"Effects of six months treatment with liraglutide among patients with psoriasis and obesity, beyond metabolic control?","volume":"164","author":"Nicolau","year":"2025","journal-title":"Med Clin (Barc)"},{"key":"2026022406165968000_llaf473-B14","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026022406165968000_llaf473-B15"},{"key":"2026022406165968000_llaf473-B16","first-page":"692","article-title":"Adaptaci\u00f3n transcultural al espa\u00f1ol del cuestionario Dermatology Life Quality Index (DLQI): El \u00cdndice de Calidad de Vida en Dermatolog\u00eda","volume":"89","author":"de Tiedra","year":"1998","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"issue":"Suppl. 1","key":"2026022406165968000_llaf473-B17","first-page":"74","article-title":"Nutritional ultrasound\u00ae: conceptualisation, technical considerations and standardisation","volume":"70","author":"Garc\u00eda-Almeida","year":"2023","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"key":"2026022406165968000_llaf473-B18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1089\/aid.2021.0141","article-title":"Ultrasound-based assessment of preperitoneal fat as a surrogate marker of cardiovascular risk: comparative study between people living with HIV and controls","volume":"38","author":"Bonjoch","year":"2022","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2026022406165968000_llaf473-B19","doi-asserted-by":"crossref","first-page":"10449","DOI":"10.3390\/ijms241310449","article-title":"Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials","volume":"24","author":"Popoviciu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026022406165968000_llaf473-B20","doi-asserted-by":"crossref","first-page":"106320","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"key":"2026022406165968000_llaf473-B21","doi-asserted-by":"crossref","first-page":"175439","DOI":"10.1016\/j.ejphar.2022.175439","article-title":"Alternative role of glucagon-like peptide-1 receptor agonists in neurodegenerative diseases","volume":"938","author":"Chen","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"2026022406165968000_llaf473-B22","first-page":"16658","article-title":"Role of glucagon-like peptide-1 receptor agonists in the treatment of obesity, cardiovascular disease, and cerebrovascular disease","volume":"134","author":"Tirandi","year":"2024","journal-title":"Pol Arch Intern Med"},{"key":"2026022406165968000_llaf473-B23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/2042018814543483","article-title":"Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis","volume":"5","author":"Al-Badri","year":"2014","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2026022406165968000_llaf473-B24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/jdv.12629","article-title":"Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients \u2013 a randomized placebo-controlled trial","volume":"29","author":"Faurschou","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026022406165968000_llaf473-B25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ad.2023.06.017","article-title":"Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases","volume":"115","author":"Vilarrasa","year":"2024","journal-title":"Actas Dermosifiliogr"},{"key":"2026022406165968000_llaf473-B26","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/09546634.2021.1882658","article-title":"Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies","volume":"33","author":"Chang","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2026022406165968000_llaf473-B27","first-page":"23","article-title":"Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes","volume":"2023","author":"Malavazos","year":"2023","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"2026022406165968000_llaf473-B28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/biom15010046","article-title":"Effects of semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label, randomized clinical trial","volume":"15","author":"Petkovi\u0107-Dabi\u0107","year":"2025","journal-title":"Biomolecules"},{"key":"2026022406165968000_llaf473-B29","first-page":"e43790","article-title":"The relationship of hematological parameters and C-reactive protein (CRP) with disease presence, severity, and response to systemic therapy in patients with psoriasis","volume":"15","author":"\u015eener","year":"2023","journal-title":"Cureus"},{"key":"2026022406165968000_llaf473-B30","doi-asserted-by":"crossref","first-page":"378","DOI":"10.5021\/ad.2019.31.4.378","article-title":"Association between homocysteine levels and psoriasis: a meta-analysis","volume":"31","author":"Kim","year":"2019","journal-title":"Ann Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf473\/64937473\/llaf473.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/3\/442\/64937473\/llaf473.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/3\/442\/64937473\/llaf473.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:17:05Z","timestamp":1771931825000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/3\/442\/8301164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,10,25]]},"published-print":{"date-parts":[[2026,2,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf473","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,10,25]]}}}